AI, robotics and biotech funding and market activity in August 2026
Recent seed, series and IPO rounds across AI, robotics and biotech illustrate capital deployment into model development, automation and gene‑editing therapies.
Compiled automatically from the sources listed below and checked against Hyperuranios' own capital and research data. Every figure here traces to a linked source. Factual errors reported to the contact address are corrected in the article and noted here.
Artificial Intelligence
Pathway, a Palo Alto‑based AI research lab, closed a $30 million seed round that valued the company at $500 million, with participation from Id4 Ventures, TQ Ventures, Red Bridge Ventures, Kadmos Capital and WS Investment Co., the investment arm of Wilson Sonsini, alongside angel investor Jonathan Frankle of Databricks. The capital will be used to expand high‑performance computing capacity, notably by acquiring next‑generation NVIDIA Blackwell/GB300 systems, and to accelerate the creation of specialised inference models for the financial services, technology and healthcare sectors. [1]
Robotics
According to the Association for Advancing Automation, North American manufacturers ordered 8,940 industrial robots in Q2 2026, generating $622 million in revenue – a 21.3 percent increase year‑on‑year. Non‑automotive customers accounted for 56 percent of units, driven by growth in automotive components (+24 percent units) and food and consumer goods (+17 percent units). Collaborative robots represented 15.4 percent of all units and 9.8 percent of revenue, with 2,774 units valued at $114 million. The data show continued diversification of automation investment despite broader economic uncertainty. [3]
Australian automation specialist Robotic Automation, founded in 1988, was acquired by the engineering and manufacturing group Varley Group, creating an Australian‑owned platform for automation, robotics and emerging technologies. The new ownership structure is intended to provide increased investment, expanded engineering resources, greater project‑delivery capacity and national service coverage, while preserving existing customer relationships and local jobs. Financial terms of the transaction were not disclosed. [4]
Genetic Engineering
AI‑native biotech Aureka Biotechnologies announced a $100 million Series B round that brings its total funding to nearly $200 million. The first tranche was funded exclusively by Granite Asia, followed by a strategic lead investor and participation from HighLight Capital and existing shareholders. The company will deploy the capital to scale research and large‑scale training of its next‑generation biological foundation models, enhancing capabilities in molecular design and structure prediction as part of its closed‑loop AI‑agent drug‑discovery platform. [2]
Epicrispr Biotechnologies closed an oversubscribed $90 million Series C financing co‑led by Octagon Capital and Janus Henderson Investors, with new participation from Fidelity Management & Research, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, abrdn‑managed funds, Angelini Ventures, Readout Capital and existing backers. The proceeds will fund pivotal clinical studies of EPI‑321, the first epigenetic therapy for facioscapulohumeral muscular dystrophy, and expand the company’s Gene Expression Modulation System platform and manufacturing capabilities. [5]
Ocugen Inc. secured a $130 million convertible senior note financing, generating about $112.5 million of net proceeds after exercising a $15 million over‑allotment option. The company used roughly $32.7 million of the funds to retire a high‑interest loan from Avenue Capital and will apply the remaining capital to extend its cash runway to 2028 while increasing spending on late‑stage retinal gene‑therapy programmes targeting geographic atrophy, retinitis pigmentosa and Stargardt disease, including pivotal Phase 3 trials and manufacturing scale‑up. [6]